How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins

European Psychiatry

Volumn 24, Issue 3, 2009, Pages 164-170

  Starrenburg, F C J ^a   Bogers, J P A M ^b  

^a Rivierduinen Psychiatric Centre   (Netherlands)

^b Rivierduinen Psychiatric Centre   (Netherlands)

Author keywords

Adipocytokines; Antipsychotics; Diabetes mellitus; Glucose; Receptor binding; Weight

Indexed keywords

ADIPONECTIN; ALPHA ADRENERGIC RECEPTOR; AMITRIPTYLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR; CLONIDINE; CLOZAPINE; DOXEPIN; DULOXETINE; FLUOXETINE; HISTAMINE RECEPTOR; HUMORAL ANTIBODY; LEPTIN; MOOD STABILIZER; MUSCARINIC M3 RECEPTOR; NEUROLEPTIC AGENT; NISOXETINE; OLANZAPINE; QUETIAPINE; RECOMBINANT LEPTIN; RISPERIDONE; SEROTONIN RECEPTOR; SERTINDOLE; SIBUTRAMINE; TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE; YOHIMBINE; ZIPRASIDONE;

ADIPOSE TISSUE; DIABETES MELLITUS; DIABETOGENESIS; DRUG ANTAGONISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LIVER; NONHUMAN; OBESITY; PANCREAS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RISK FACTOR; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; SKELETAL MUSCLE; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPONECTIN; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CLOZAPINE; DIABETES MELLITUS; HUMANS; LEPTIN; OBESITY; PIPERAZINES; QUINOLONES; RECEPTOR, MUSCARINIC M3; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; RECEPTORS, HISTAMINE; THIAZOLES; WEIGHT GAIN;

EID: 63749126381     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.01.001     Document Type: Short Survey

References (66)

1. Altman J.D., Trendelenburg A.U., MacMillan L., Bernstein D., Limbird L., Starke K., et al. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 56 1 (1999 Jul) 154-161
2. Ardizzone T.D., Bradley R.J., Freeman III A.M., and Dwyer D.S. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 923 1-2 (2001 Dec 27) 82-90
3. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65 10 (2004 Oct) 1335-1342
4. Auwerx J., and Staels B. Leptin. Lancet 351 9104 (1998 Mar 7) 737-742
5. Basile V.S., Masellis M., McIntyre R.S., Meltzer H.Y., Lieberman J.A., and Kennedy J.L. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 23 Suppl. 62 (2001) 45-66
6. Bergman R.N., and Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 66 4 (2005 Apr) 504-514
7. Bjorbaek C., El-Haschimi K., Frantz J.D., and Flier J.S. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 274 42 (1999 Oct 15) 30059-30065
8. Boehm G., Racoosin J.A., Laughren T.P., and Katz R. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 27 8 (2004 Aug) 2088-2089 author reply 9-90
9. Cassidy F., Ahearn E., and Carroll B.J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 156 9 (1999 Sep) 1417-1420
10. Chang J.S., Ahn Y.M., Park H.J., Lee K.Y., Kim S.H., Kang U.G., et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69 5 (2008 May) 720-731
11. Citrome L., Jaffe A., Levine J., Allingham B., and Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55 9 (2004 Sep) 1006-1013
12. Colli A., Cocciolo M., Francobandiera F., Rogantin F., and Cattalini N. Diabetic ketoacidosis associated with clozapine treatment. Diabetes Care 22 1 (1999 Jan) 176-177
13. Ebenbichler C.F., Laimer M., Eder U., Mangweth B., Weiss E., Hofer A., et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 64 12 (2003 Dec) 1436-1439
14. E.M.E.A. EMEA. Scientific discussion. Available from (2005). www.emea.europa.eu/humandocs/PDFs/EPAR/abilify/089304en6.pdf
15. Farooqi I.S., Matarese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110 8 (2002 Oct) 1093-1103
16. Gautam D., Han S.J., Hamdan F.F., Jeon J., Li B., Li J.H., et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 3 6 (2006 Jun) 449-461
17. Gianfrancesco F.D., Grogg A.L., Mahmoud R.A., Wang R.H., and Nasrallah H.A. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63 10 (2002 Oct) 920-930
18. Gromada J., and Hughes T.E. Ringing the dinner bell for insulin: muscarinic M3 receptor activity in the control of pancreatic beta cell function. Cell Metab 3 6 (2006 Jun) 390-392
19. Hagg S., Joelsson L., Mjorndal T., Spigset O., Oja G., and Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 59 6 (1998 Jun) 294-299
20. Hagg S., Soderberg S., Ahren B., Olsson T., and Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 62 11 (2001 Nov) 843-848
21. Hanssens L., van Winkel R., Wampers M., Van Eyck D., Scheen A., Reginster J.Y., et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 106 2-3 (2008 Dec) 308-314
22. Havel P.J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 1 Suppl. 53 (2004 Feb) S143-S151
23. Hayashi A., Sonoda R., Kimura Y., Takasu T., Suzuki M., Sasamata M., et al. Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Brain Res 1011 2 (2004 Jun 18) 221-227
24. Henderson D.C. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 23 Suppl. 62 (2001) 39-44
25. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62 1 (2005 Jan) 19-28
26. Howes O.D., Bhatnagar A., Gaughran F.P., Amiel S.A., Murray R.M., and Pilowsky L.S. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 161 2 (2004 Feb) 361-363
27. Jackson H.C., Needham A.M., Hutchins L.J., Mazurkiewicz S.E., and Heal D.J. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 121 8 (1997 Aug) 1758-1762
28. Jeanrenaud B. An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause. Diabetologia 28 8 (1985 Aug) 502-513
29. Jindal R.D., and Keshavan M.S. Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology. J Clin Psychopharmacol 26 5 (2006 Oct) 449-450
30. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54 5 (2005 May) 1552-1558
31. Kabinoff G.S., Toalson P.A., Healey K.M., McGuire H.C., and Hay D.P. Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. Prim Care Companion J Clin Psychiatry 5 1 (2003 Feb) 6-14
32. Kern P.A., Ranganathan S., Li C., Wood L., and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280 5 (2001 May) E745-E751
33. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 9 (1998 Sep) 1414-1431
34. Kopelman P.G., and Albon L. Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome. Br Med Bull 53 2 (1997) 322-340
35. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kuhn M., Uhr M., et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156 2 (1999 Feb) 312-314
36. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 3 (2003 Mar) 519-526
37. Laimer M., Ebenbichler C.F., Kranebitter M., Eder U., Mangweth B., Weiss E., et al. Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors. J Clin Psychopharmacol 25 2 (2005 Apr) 183-185
38. Leibowitz S.F., Roossin P., and Rosenn M. Chronic norepinephrine injection into the hypothalamic paraventricular nucleus produces hyperphagia and increased body weight in the rat. Pharmacol Biochem Behav 21 5 (1984 Nov) 801-808
39. Leslie D.L., and Rosenheck R.A. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161 9 (2004 Sep) 1709-1711
40. Lindenmayer J.P., Nathan A.M., and Smith R.C. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 23 Suppl. 62 (2001) 30-38
41. Masaki T., Chiba S., Yasuda T., Noguchi H., Kakuma T., Watanabe T., et al. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 53 9 (2004 Sep) 2250-2260
42. Masaki T., Yoshimatsu H., Chiba S., Watanabe T., and Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 50 2 (2001 Feb) 385-391
43. McIntyre R.S., Mancini D.A., and Basile V.S. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 23 Suppl. 62 (2001) 23-29
44. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 14 2 (2004 Mar) 115-119
45. Melkersson K.I., and Dahl M.L. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 170 2 (2003 Nov) 157-166
46. Melkersson K.I., Hulting A.L., and Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61 10 (2000 Oct) 742-749
47. Montague C.T., Farooqi I.S., Whitehead J.P., Soos M.A., Rau H., Wareham N.J., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387 6636 (1997 Jun 26) 903-908
48. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13 1 (2008 Jan) 27-35
49. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59 4 (2002 Apr) 337-345
50. Nilsson T., Arkhammar P., Rorsman P., and Berggren P.O. Inhibition of glucose-stimulated insulin release by alpha 2-adrenoceptor activation is paralleled by both a repolarization and a reduction in cytoplasmic free Ca2+ concentration. J Biol Chem 263 4 (1988 Feb 5) 1855-1860
51. O'Neill M.F. Unusual suspect for antipsychotic-induced diabetes. Drug Discov Today 10 20 (2005 Oct 15) 1338
52. Peterson H.R., Rothschild M., Weinberg C.R., Fell R.D., McLeish K.R., and Pfeifer M.A. Body fat and the activity of the autonomic nervous system. N Engl J Med 318 17 (1988 Apr 28) 1077-1083
53. Pollmacher T., Hinze-Selch D., and Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16 5 (1996 Oct) 403-409
54. Popli A.P., Konicki P.E., Jurjus G.J., Fuller M.A., and Jaskiw G.E. Clozapine and associated diabetes mellitus. J Clin Psychiatry 58 3 (1997 Mar) 108-111
55. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160 2 (2003 Feb) 284-289
56. Sakata T., Ookuma K., Fukagawa K., Fujimoto K., Yoshimatsu H., Shiraishi T., et al. Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res 441 1-2 (1988 Feb 16) 403-407
57. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124 1-2 (1996 Mar) 57-73
58. Seufert J., Kieffer T.J., Leech C.A., Holz G.G., Moritz W., Ricordi C., et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 84 2 (1999 Feb) 670-676
59. Silvestre J.S., and Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 27 5 (2005 Jun) 289-304
60. Sonnenberg G.E., Krakower G.R., and Kissebah A.H. A novel pathway to the manifestations of metabolic syndrome. Obes Res 12 2 (2004 Feb) 180-186
61. Spoelstra J.A., Stolk R.P., Cohen D., Klungel O.H., Erkens J.A., Leufkens H.G., et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry 65 5 (2004 May) 674-678
62. Sprouse J.S., Reynolds L.S., Braselton J.P., Rollema H., and Zorn S.H. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 21 5 (1999 Nov) 622-631
63. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 9467 (2005 Apr) 1333-1346
64. van Winkel R., De Hert M., Wampers M., Van Eyck D., Hanssens L., Scheen A., et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 69 3 (2008 Mar) 472-479
65. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60 6 (1999 Jun) 358-363
66. Zimmermann U., Kraus T., Himmerich H., Schuld A., and Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37 3 (2003 May-Jun) 193-220